
    
      To evaluate the effectiveness of intravenous rhTPO vs. placebo as primary prophylaxis in
      reducing the cumulative proportion of patients requiring platelet transfusion for severe
      chemotherapy-induced thrombocytopenia (platelet count <15,000) during the first four study
      cycles. To evaluate the severity and duration of thrombocytopenia and neutropenia associated
      with rhTPO prophylaxis, the impact of rhTPO prophylaxis on health economics/cost
      effectiveness, and patient quality of life. To assess the safety of multiple IV doses of
      rhTPO.
    
  